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Abstract To explore the relative roles of the two C1 domains of
protein kinase C alpha (PKCK) in the response to phorbol esters
and related analogs, we mutated the individual C1 domains,
expressed the mutated PKCK in NIH 3T3 cells, and then
examined the ability of ligands to induce its translocation to the
membrane. The C1a and C1b domains play equivalent roles for
translocation in response to phorbol 12-myristate 13-acetate,
mezerein, and (3)octylindolactam V. These results contrast with
those previously reported for PKCN, suggesting that the domains
play different roles in different PKC isoforms.
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1. Introduction
The lipophilic second messenger sn-1,2-diacylglycerol sig-
nals through interaction with the C1 domains present on pro-
tein kinase C (PKC) isoforms [1,2], as well as on the chimaer-
ins [3,4] and on RasGRP [5]. Several structurally distinct
classes of natural products including the phorbol ester tumor
promoters and the indole alkaloids function as potent analogs
of diacylglycerol, likewise interacting with the C1 domains [6].
The structure of the complex between the second C1 domain
of PKCN and phorbol 13-acetate has been solved by X-ray
crystallography [7], and insight into the interactions with oth-
er ligands has been provided by computer modeling [8].
Unlike the chimaerins and RasGRP, PKC possesses tan-
dem C1 domains. The relative involvement of these two C1
domains in the response to the phorbol esters and related
ligands remains uncertain, however. Using isolated C1 do-
mains, Irie et al. [9] have suggested that only the C1b domain
of most PKC isoforms, including PKCK, recognizes phorbol
esters. In contrast, studies using intact PKC and a variety of
methodological approaches have suggested that both domains
function, but with varying contributions depending on the
speci¢c ligand [10^13].
The approach we have taken has been to mutate either the
C1a, C1b, or both domains so as to reduce the a⁄nity of
interaction without abolishing activity or causing gross dis-
ruption of the structure. The mutated PKC has then been
expressed in NIH 3T3 cells and its response to ligand moni-
tored by the ability of ligand to induce translocation from the
cytosol to the membrane. Using PKCN, we have reported that
translocation in response to phorbol 12-myristate 13-acetate
(PMA) depends on the C1b domain, but with a further con-
tribution by the C1a domain evident in the double mutant
[14]. The indole alkaloid (3)octylindolactam V (octyl-ILV)
showed behavior similar to that for PMA [13]. Mezerein, in
contrast, showed equivalence between the two C1 domains,
with either the C1a or C1b mutants showing a comparable
decrease in potency for translocation [13]. Shieh et al., using
deletions of either the C1a or C1b domains of PKCK, had
likewise described di¡erent dependence on the C1a and C1b
domains for di¡erent ligands, using e¡ects on cell prolifera-
tion in yeast as an endpoint [11,12]. However, their conclu-
sions di¡ered regarding the pattern of dependence for di¡er-
ent ligands. Thus, in their studies PMA showed equal
dependence on C1a and C1b, mezerein depended on C1a,
and octyl-ILV required both C1a and C1b for activity. These
di¡erences could have re£ected the isoform, the cell system, or
the nature of the alterations in the C1 domains. In the present
study, we have extended our previous approach to PKCK. We
conclude that di¡erent PKC isotypes, under parallel condi-
tions, show di¡erent dependence on the C1a and C1b domains
for ligand driven translocation.
2. Materials and methods
2.1. Materials
Phorbol 12-myristate 13-acetate (PMA), mezerein, and (3)octylin-
dolactam V were purchased from Alexis Corporation (San Diego, CA,
USA).
2.2. Site-directed mutagenesis of PKCK
The bovine PKCK was subcloned by polymerase chain reaction
(PCR) into the pGEM-T vector (Promega, Madison, WI, USA) using
the 5P oligonucleotide CGCTCGAGATGGCTGACGTCTTCC (con-
taining the underlined XhoI site) and the 3P oligonucleotide CG-
ACGCGTTACCGCGCTCTGCAGGATGG (containing the under-
lined MluI site). The PCR reaction was carried out for eight cycles
using the high ¢delity thermostable Vent DNA Polymerase (New
England Biolabs, Beverly, MA, USA). The ¢delity of the PCR reac-
tion was con¢rmed by direct sequencing. This plasmid served as our
‘master’ vector for the subsequent mutagenesis. Site-directed muta-
genesis was performed using the Transformer Site-directed Mutagen-
esis Kit from Clontech (Palo Alto, CA, USA). The following oligo-
nucleotides served as primers for selection and mutagenesis: (1) 5P-
CGCCTGCAGATCGATCATATGGGAGAG-3P changes the SalI
site present in the pGEM-T vector at position 75 into the underlined
ClaI restriction site. (2) 5P-CGCTTCTTCAAGCAGGGTACCTT-
CTGCAGC-3P mutates the proline residue at position 47 into glycine
(bold letters) and creates the underlined KpnI restriction site to facil-
itate the detection of mutant plasmids. (3) 5P-ACGTATGG-
CAGCGGTACCTTCTGTGAT-3P mutates the proline residue in po-
sition 112 into glycine (bold letters) and creates the underlined KpnI
restriction site to facilitate the detection of mutant plasmids. The
mutations were con¢rmed by direct sequencing (Paragon Biotech
Inc., Baltimore, MD, USA). The single mutants proline to glycine
at site 47 (P47G), proline to glycine at site 112 (P112G), and the
double mutant (P47/112G) were subcloned along with the wild-type
into an epitope tagging mammalian expression vector described in
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detail by Olah et al. [15]. The XhoI and MluI restriction sites ensure
unidirectionality and the vector attaches to the end of PKCK a
C-terminal 12 amino acid tag, originally derived from the C-terminal
sequence of PKCO.
2.3. Cell culture and transfection of cells
NIH 3T3 ¢broblasts were grown in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 4500 mg/l glucose, 4 mM L-glutamine,
50 U/ml penicillin, 50 Wg/ml streptomycin (Advanced Biotechnologies
Inc., Columbia, MD, USA) and 10% fetal calf serum (complete
DMEM) (Gibco BRL-Life Technologies, Gaithersburg, MD, USA).
The cells were transfected with the wild-type and mutant constructs
using Lipofectamine (Gibco BRL-Life Technologies, Gaithersburg,
MD, USA) and selected as described previously [16]. For the assess-
ment of the amounts of soluble and membrane-associated mutant and
wild-type PKCK, the cells were incubated with di¡erent concentra-
tions (1 nM^30 WM) of PMA, mezerein, and octyl-ILV (Alexis
Corp. San Diego, CA, USA) for 30 min, 1 h, 3 h, or 6 h at 37‡C.
All compounds were dissolved in dimethyl sulfoxide (DMSO) such
that the ¢nal concentration of DMSO in the medium was 0.1%, in-
cluding for the control cells.
2.4. Cell lysis and Western blot analysis
The cells were harvested and lysed, and the soluble and Triton
X-100-soluble particulate fractions were prepared as described previ-
ously [16]. The protein content of the cytosolic fraction was measured
by a micromethod using the Bio-Rad Protein Assay (Bio-Rad Labo-
ratories, Hercules, CA, USA). Twelve Wg protein of the cytosolic
fraction were mixed with equal volumes of 2USDS sample bu¡er
(125 mM Tris-Cl, pH 6.8, 20% glycerol, 4% SDS, 0.71 M L-mercap-
toethanol and bromophenol blue) and subjected to SDS-PAGE using
8% polyacrylamide gels (Novex, San Diego, CA, USA) followed by
electrotransfer onto nitrocellulose membranes. The membranes were
immunostained using the polyclonal anti-PKCO antibody (Gibco
BRL-Life Technologies, Gaithersburg, MD, USA) applied as de-
scribed previously [16]. Densitometric analysis was performed under
conditions that yielded a linear response and analyzed using the Na-
tional Institutes of Health Image 1.52 program (written by Dr. Wayne
Raspband, National Institutes of Health).
3. Results and discussion
We compared the ability of ligands to induce translocation
of PKCK wild-type and mutants using epitope-tagged enzyme
expressed in NIH 3T3 cells. We have previously described that
neither the overexpression nor the epitope tag a¡ect the ED50
of PKCK for translocation; likewise, they do not a¡ect the
subcellular fraction to which it translocates [13,14,16]. Trans-
location was quantitated by Western blotting, assessing the
decrease in the level of PKCK present in the soluble fraction.
The level of total PKCK was monitored in parallel to con¢rm
that observed decreases were not due to down regulation of
the enzyme over the time period examined. All data re£ect 4^6
independent experiments.
Measurement of translocation was determined as a function
of dose of ligand and of time. The three ligands examined
were PMA, mezerein, and octyl-ILV. The incubation times
were 30 min, 1, 3, and 6 h. For all three ligands, the dose
response curves were independent of time by 3 h, and at this
time the level of PKCK had not yet begun to decrease due to
down regulation over the range of ligand concentrations de-
¢ning the curves (data not shown). The dose response curves
for translocation, representing the averaged data for the 3 h
incubation, are illustrated in Fig. 1. Representative Western
C
Fig. 1. PMA (A), mezerein (B), and octyl-ILV (C) induced changes
in levels of wild-type and mutant PKCK in the cytosolic fraction of
NIH 3T3 ¢broblasts. NIH 3T3 ¢broblasts transfected with the wild-
type or mutant forms of PKCK were treated with the indicated
doses of PMA, mezerein, or octyl-ILV for 3 h. The soluble fraction
was prepared for SDS-PAGE, and Western immunoblotting was
performed as described in Section 2. The amount of the enzyme
was quantitated by densitometry and expressed as the percentage of
the amount of isozyme present in the soluble fraction in the control.
The illustrated curves are calculated from the Hill equation. Points
represent the average of four to six independent experiments þ
S.E.M.
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blots are shown in Fig. 2. The ED50 values are summarized in
Table 1.
PMA translocated wild-type PKCK with an ED50 of 12 nM
(Fig. 1A). Mutations in either the C1a or the C1b domain
caused shifts of 18-fold and 31-fold, respectively. It is thus
clear that both C1 domains make a major contribution to
PMA induced translocation, although there is a modestly
greater contribution by the C1b domain. For the PKCK dou-
ble mutant, there was only a small (2^3-fold) additional shift
in the ED50 for PMA compared to that of the single mutants.
These results contrast markedly with those obtained previ-
ously for PKCN [14]. In that case, the shifts in ED50 had
been 1.1- and 18-fold for the C1a and C1b mutants, respec-
tively, and the C1a/C1b double mutant had shown a further
shift in its ED50 to 127-fold that of the wild-type.
Mezerein translocated wild-type PKCK with an ED50 of 33
nM; it was thus slightly less potent than PMA (Fig. 1B).
Mutations in the C1a and C1b domains caused closely com-
parable 3- and 4-fold shifts. The double mutant showed a 60-
fold shift in ED50. The results of the single mutants are qual-
itatively similar to those observed with PKCN [13], where the
two C1 domains were basically equivalent, with 14- and 18-
fold shifts. Although the double mutant behaved in a quali-
tatively similar fashion for PKCK and PKCN, quantitatively
the loss of a⁄nity was less for PKCK. In the case of PKCN,
negligible decrease was detected up to 30 WM.
Octyl-ILV translocated wild-type PKCK with an ED50 of 36
nM (Table 1). It thus is similar in potency to mezerein. The
mutations in the C1a and C1b mutations caused comparable
29- and 45-fold shifts in ED50, respectively. The double mu-
tant displayed an additional shift, but its magnitude could not
be assessed because of the weak response. In the case of
PKCN, the C1 domains had not been equivalent for recogni-
tion of octyl-ILV [13]. The mutants in the C1a and C1b do-
mains had displayed shifts of 1.5- and 20-fold, respectively,
analogous to the behavior of PMA [13,14]. The shift for the
double mutant had been 364-fold. Octyl-ILV thus resembles
PMA in the di¡erence in its C1 domain dependence between
PKCK and PKCN, shifting from dependence primarily on C1b
in PKCN to equivalence of C1a and C1b in PKCK.
Our ¢ndings have several important implications. First, it is
clear that all PKC isoforms cannot be treated as equivalent
with regard to the role of the C1 domains. Rather, for de-
tailed understanding of their function and involvement in
structure-activity relations, the behavior of the individual iso-
forms will need to be individually characterized. This perhaps
should not be a surprise, in that the isoforms di¡er with
regard to many of their other structural properties. PKCN
Fig. 2. Dose-dependent translocation of the wild-type and mutant
forms of PKCK by PMA (A), mezerein (B), and octyl-ILV (C).
NIH 3T3 ¢broblasts overexpressing the wild-type or mutant forms
of PKCK were treated by the indicated doses of PMA, octyl-ILV,
and mezerein for 3 h. The soluble fraction was prepared for SDS-
PAGE, and Western immunoblotting was performed as described in
Section 2. Equal amounts of protein of the cytosolic fraction (12 Wg
of protein/lane) were loaded in each lane. Similar results were ob-
tained in four^six sets of independent experiments for each ligand.
Table 1
Potencies of PMA, mezerein, and octyl-ILV to induce translocation
of the wild-type and mutant forms of PKCK
ED50 (nM)
PMA Mezerein Octyl-ILV
PKCK wild-type 12 þ 1 33 þ 6 36 þ 4
PKCK P47G 216 þ 29 100 þ 20 1030 þ 110
PKCK P112G 368 þ 59 119 þ 23 1620 þ 180
PKCK P47/112G 644 þ 88 1970 þ 370 n.d.
ED50 values were determined from ¢tting of the data to the Hill
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shows di¡erent dependence on phosphorylation in the activa-
tion loop for activation of kinase activity [17]. PKCO has been
reported to show distinct phospholipid dependence [18].
PKCR is selectively activated by cholesterol sulfate [19].
We had described previously that the ability of ligands to
cause translocation of PKC depends not only on the C1 do-
main but also on the molecular context in which that domain
is found [16]. PKCK was induced to translocate with 30-fold
weaker ED50 than was a chimera containing the regulatory
domain of PKCK and the catalytic domain of PKCO [16].
Presumably, the mechanism is related to the coupling between
the conformational changes associated with ligand binding
and translocation and the contributions of other structural
elements in PKC to the stabilization of the di¡erent confor-
mations. Oancea and Meyer have elegantly demonstrated con-
tributions to translocation of PKCQ by the pseudosubstrate
region and the C2 domain as well as by the C1 domains
[20]. Such di¡erences may contribute to the di¡erent behavior
of di¡erent isoforms.
The C1 domains of the various diacylglycerol/phorbol ester
receptors show substantial conservation. The roles of other
structural features in determining the response of the intact
proteins to their ligands provides abundant further opportu-
nities for the establishment of selectivity. An on-going chal-
lenge is to understand these di¡erences at the mechanistic
level, so that they can be exploited in a rational rather than
simply an empirical fashion.
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